Top 7 Innovations in the Anti-Peptic Ulcer Drugs Industry According to a newly published market research report by 24LifeSciences, global anti-peptic ulcer drugs market was valued at USD 10.21 billion in 2024 and is projected to reach USD 25.80 billion by 2031, growing at a compound annual growth rate (CAGR) of 14.5% during the forecast period 2025–2031. Anti-peptic ulcer drugs encompass a range of pharmaceutical agents that prevent, manage, or heal ulcers in the stomach and duodenum. This market includes several drug classes with distinct mechanisms of action, such as proton pump inhibitors (PPIs) that profoundly suppress acid production, H2 receptor antagonists that reduce acid secretion, antacids that neutralize existing stomach acid, and mucosal protective agents that strengthen the stomach's natural defenses. The established efficacy of these drugs, particularly in managing conditions like gastroesophageal reflux disease (GERD), gastric ulcers, and duodenal ulcers, continues to underpin their critical role in gastroenterological practice worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/7579/anti-peptic-ulcer-drugs-market-market

What Is the Future of the Gastrointestinal Therapeutics Market? Growth Forecasts According to a newly published market research report by 24LifeSciences, global gastrointestinal therapeutics market is valued at USD 35,410 million in 2026 and is projected to reach USD 51,860 million by 2034, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period. Gastrointestinal therapeutics comprise a critical class of pharmaceuticals designed to treat a wide range of disorders affecting the digestive system, from the esophagus to the colon. This includes prevalent conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and inflammatory bowel disease (IBD). The therapeutic arsenal includes well-established drugs like proton pump inhibitors, biologics, and antacids, commercially available under brands such as Aciphex (rabeprazole) and Prilosec (omeprazole). The sustained efficacy and expanding applications of these treatments continue to underpin their importance in both primary care and specialized gastroenterology practice. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8881/gastrointestinal-therapeutics-market